Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
National
Henry Saker-Clark

Novo Nordisk boosted as sales of Wegovy weight loss pills soar

  • Pharmaceutical firm Novo Nordisk is expected to surpass its trading forecasts, driven by the high demand for its new Wegovy weight loss pill.
  • Shares in the Copenhagen-based company rose following the announcement, as Wegovy's January launch directly challenged rival Eli Lilly's Mounjaro.
  • Wegovy has achieved the strongest debut for any obesity drug in the US market, with over two million prescriptions issued and weekly figures exceeding 200,000.
  • The pill generated 2.26 billion Danish krone (£261 million) in sales during the quarter ending 31 March, surpassing analyst predictions.
  • Despite a dip in adjusted net sales and operating profit for the quarter, Novo Nordisk has raised its 2026 guidance for both adjusted sales and operating profit, citing Wegovy's strong performance.

IN FULL

Novo Nordisk shares soar as sales of Wegovy weight loss pill smash forecasts

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.